Financials

News Ideas Discussions Technicals Seasonals

VXL fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The firm's pipeline consists of ImMucin, SPmAb2, SPmAb6, and MTbuVax. The company was founded on July 26, 2006 and is headquartered in Toronto, Canada.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

VXL has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company